ReviewExperimental cell research2014
Getting more for your marrow: boosting hematopoietic stem cell numbers with PGE2.
Review in Experimental cell research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 59 citations in OpenAlex.
- Ex Vivo Expansion of Cord Blood Hematopoietic Stem and Progenitor Cells.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Prostaglandin EEXCLI journal · 2025Review
- Flight for fish in drug discovery: a review of zebrafish-based screening of molecules.Biology letters · 2023Review
- Article
- Development and clinical advancement of small molecules forActa pharmaceutica Sinica. B · 2022Review
- Article
- Prostaglandin EStem cell reviews and reports · 2021Article
- A versatile, automated and high-throughput drug screening platform for zebrafish embryos.Biology open · 2021Article
- Long-acting PGE2 and Lisinopril Mitigate H-ARS.Radiation research · 2021Article
- Article
- Apoptosis - Fueling the oncogenic fire.The FEBS journal · 2021Review
- Phenotypic technologies in stem cell biology.Cell chemical biology · 2021Review
- [Metabolism and transport pathway of prostaglandin E2 and its role in liver regeneration].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021Review
- Effect of Small Molecule onFrontiers in cell and developmental biology · 2021Review
- Absence of CD11a Expression Identifies Embryonic Hematopoietic Stem Cell PrecursorsFrontiers in cell and developmental biology · 2021Article
- Mechanistic Basis of ex Vivo Umbilical Cord Blood Stem Progenitor Cell Expansion.Stem cell reviews and reports · 2020Review
- A Role for Lipid Mediators in Acute Myeloid Leukemia.International journal of molecular sciences · 2019Review
- Rescue from lethal acute radiation syndrome (ARS) with severe weight loss by secretome of intramuscularly injected human placental stromal cells.Journal of cachexia, sarcopenia and muscle · 2018Article
- Endometrial Stem Cells in Farm Animals: Potential Role in Uterine Physiology and Pathology.Bioengineering (Basel, Switzerland) · 2018Review
- The CD11a and Endothelial Protein C Receptor Marker Combination Simplifies and Improves the Purification of Mouse Hematopoietic Stem Cells.Stem cells translational medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Throughout the lifetime of an individual, hematopoietic stem cells (HSCs) self-renew and differentiate into lineages that include erythrocytes, platelets and all immune cells. HSC transplantation offers a potentially curative treatment for a number of hematopoietic and non-hematopoietic malignancies as well as immune and genetic disorders. Limited availability of immune-matched donors reduces the viable options for many patients in need of HSC transplantation, particularly those of diverse racial and ethnic backgrounds. Due to rapid availability and less stringent immune-matching requirements, umbilical cord blood (UCB) has emerged as a valuable source of transplantable HSCs. A single UCB unit contains a suboptimal number of HSCs for treating larger children or adults and there has thus been great clinical interest in expanding UCB HSCs ex vivo for use in transplantation. In this review we discuss the latest research and future avenues for the therapeutic use of small lipid mediator dmPGE2 to expand HSC numbers for transplantation. Originally identified in a chemical screen in zebrafish, dmPGE2 has now advanced to a phase II clinical trial as a therapy for patients with leukemia and lymphoma who are undergoing UCB transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.